Teriparatide

Other FDA-approved drug

Parathyroid hormone analog (PTH 1-34) · also known as Forteo, PTH(1-34), rhPTH(1-34)

For reference only — not medical advice. Figures are commonly reported values compiled from published sources and may be wrong or out of date. Many compounds listed are not approved for human use. Talk to a licensed clinician before using any compound.

Teriparatide is an anabolic bone agent, meaning intermittent exposure favors bone formation. The US-approved product is a prefilled pen delivering 20 micrograms per day. The label advises that use beyond 2 years in a lifetime only be considered if fracture risk remains high. The 750 mcg vial in this entry is a research format whose figures are arithmetic, not the approved product.

Commonly reported dosing (0.75 mg vial)

Reconstituted with 3 mL → 0.25 mg/mL.

Phase	Dose	Volume	U-100 units
Standard Labeled daily amount for the approved pen and used in pivotal trials.	20 mcg	0.08 mL	8

Frequency: Once daily in the labeled regimen and in cited trials · Half-life: About 1 hour after subcutaneous administration (US label)

Open in calculator

Commonly reported reconstitution steps

Vials are usually brought to room temperature (about 15-20 minutes) first.
3 mL of bacteriostatic water is added slowly down the inside wall of the 0.75 mg vial.
The vial is swirled gently until clear, not shaken.
This gives 0.25 mg/mL. Mixed vials are typically labeled with the date and refrigerated.

Storage

Before mixing: The approved pen is labeled for refrigeration (2-8 °C) at all times except during use; research-vial storage is not defined by that label.

After mixing: Reconstituted solution is commonly kept refrigerated (2-8 °C) and protected from light; no compound-specific discard period is established for a mixed vial.

How it works

Activating the PTH1 receptor in short daily pulses stimulates osteoblast activity and bone formation, whereas continuous PTH exposure tends to promote bone resorption.

Researched for

Randomized trials of 20 and 40 mcg daily reduced vertebral fractures in postmenopausal women with osteoporosis.
Studied in men with osteoporosis and in glucocorticoid-induced osteoporosis.
Compared with weekly and cyclic schedules, with denosumab, and in treatment sequences.

Notes

Label-reported common adverse reactions include joint pain, pain and nausea; osteosarcoma is listed under warnings and precautions.
A 750 mcg lyophilized vial differs from the approved 250 mcg/mL pen in formulation and stability, and the two are not interchangeable.
At 3 mL, a 750 mcg vial gives 250 mcg/mL; one U-100 unit is about 2.5 mcg.
Brand-name pens and kits are pre-measured; the reconstitution figures here apply to vials that require mixing.